In cats and dogs, motility disorders of the esophagus, stomach, small intestine, and colon are common. Traditionally, these conditions have been treated primarily by dietary management and surgical intervention. In recent years, gastrointestinal prokinetic therapy has become increasingly important in the clinical management of patients with these disorders. In this five-part Continuing Education Series, the first four articles divide gastrointestinal prokinetic drugs into four groups - for each group, the mechanisms of action, site of activity, and indications are discussed. The first part provided information concerning the dopaminergic antagonist drugs. The second part considered motilin-like drugs, particularly erythromycin and the other macrolides. The third article in the series discussed serotonergic drugs, especially cisapride. This part considers the acetylcholinesterase inhibitors or parasympathetic potentiating drugs. Ranitidine and nizatidine are competitive, reversible H 2-receptor antagonists with gastric antisecretory properties. Both agents may have clinical applications in gastrointestinal prokinetic therapy that are not associated with cimetidine or famotidine. The final article of the series will discuss the diagnosis and treatment of esophageal, gastric, intestinal, and colonic motility disorders.
|Original language||English (US)|
|Number of pages||6|
|Journal||Compendium on Continuing Education for the Practicing Veterinarian|
|State||Published - May 1 1997|